Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering medicines for diseases. Co.'s pipeline includes gene therapy programs in neurologic lysosomal disorders (LDs), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder Mucopolysaccharidosis Type IIIB, as well as a program in Mucopolysaccharidosis Type IIIA. Co.'s collaboration with University of Pennsylvania also provides option rights to develop new gene therapy platform technologies and programs for most LDs and a portfolio of diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. The FOLD stock yearly return is shown above.
The yearly return on the FOLD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FOLD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|